Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA, USA Abstract: The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration&am...
Saved in:
Main Authors: | Pearre DC (Author), Tewari KS (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging treatment options for ovarian cancer: focus on rucaparib
by: Mariappan L, et al.
Published: (2017) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018) -
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
by: Alfonso Yubero, et al.
Published: (2023) -
Spotlight on pembrolizumab in the treatment of advanced melanoma
by: Rajakulendran T, et al.
Published: (2015) -
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer
by: Justin A. Harold, et al.
Published: (2018)